BlossomHill Therapeutics, Inc., a privately-held, a clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, today presented preliminary ...

FX-909, the first small molecule targeting PPARG to be tested in humans, showed monotherapy activity in advanced urothelial carcinoma with a ...

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine Aggregated TDP-43 is a pathological hallmark of ...

The FDA has approved belantamabmafodotin (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd)for the ...

South San Francisco, California Saturday, October 25, 2025, 14:00 Hrs [IST] ...

Engineered genome editors are transforming precision medicine, yet their clinical impact hinges on delivery: getting editing ...

Intranasal adrenaline represents a viable, needle-free alternative treatment for anaphylaxis, with comparable pharmacokinetics.

Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced preliminary clinical and preclinical ...

CDR-Life announces early clinical data demonstrating pharmacodynamic activity of CDR404: Zurich, Switzerland Saturday, October 25, 2025, 18:00 Hrs [IST] CDR-Life, Inc, a biotechno ...

Over the past two decades there have been tremendous advancements in the understanding of both the prevalence and the ...